PharmAsia Summit 2009
October 26-28, 2009 - San Francisco, CA

Preliminary Agenda

Monday, October 26, 2009

2:00pm Workshop Registration

2:45-4:00pm Workshop - The Do's and Don'ts of Investing in Chinese Life Sciences Companies: Effective Strategies for Getting in and Exiting - Sponsored by Ropes & Gray

This topic is important because there is a huge amount of interest among both private equity investors and strategic investors such as Western pharma companies in taking equity stakes in domestic Chinese companies in this industry. Successfully structuring the investment and enabling an eventual sale of the stake requires extensive on-the-ground experience in dealing with Chinese life sciences companies.

The ongoing reforms in the Chinese health care world have further spurred interest among strategic and private equity investors in Chinese life sciences companies, particularly companies involved in manufacturing, testing, and wholesale and retail distribution of pharmaceuticals in China. The recent resurrection of the market for IPOs in Hong Kong and, to a lesser extent, the US has also fanned interest among investors, such as the recent successful Hong Kong IPO of SinoPharm Group.

Determining valuations in a rapidly changing marketplace and regulatory environment -- bridging the gap between expectations of domestic companies and investors
Key considerations in structuring investments, including the recent increase in interest in direct onshore investments as well as compliance with the HKSE's restrictions on price-adjustable investment
Understanding how customary practices in the life sciences industry can create compliance problems which create direct risks for investors and complicate exits later on
Craft reimbursement, formulary access and comparative effectiveness strategies

the collision of industry-standard sales and marketing practices with the FCPA,
identifying and handling related party transactions,

IP ownership issues,

Planning ahead -- how to facilitate the exit

anticipating common accounting headaches (e.g., uncertainty regarding what's included and excluded from the listed company group),
handling joint venture partners or key customers who may want to delay or hinder the IPO or M&A acquisition,

keeping an eye on the listing requirements for both the Nasdaq/NYSE and Hong Kong Stock Exchange

Speakers include:

Paul Boltz, Partner, Ropes & Gray LLP
Carin Fradin, Managing Director, UBS Global Health Care
Charles Hsu, Venture Partner, Bay City Capital
Michael Li-Ming Wong, Partner, Ropes & Gray LLP

4:00-4:40pm - Networking Break

4:40-5:45pm Workshop - Accessing the Asian Pacific Market Access: Regulatory, Clinical and Reimbursement Strategies and Tactics - Sponsored by PAREXEL Consulting

The Asian Pacific market is demanding additional pharmaceutical products. Key indicators include: the opening of Japan's PMDA to global studies and to review Asian data for product registration, the dawn of a renewed SFDA in China and the Government's focus on improving patient access to medicines, viable regulatory pathways for biologics, including biosimilars, in Korea and Japan, and Taiwan positioning itself as the launch pad to the larger China market. The region's market potential for biopharma manufacturers is roughly equivalent to that of the top 5 selling countries in Europe.

It's no wonder that foreign companies are responding to this opportunity with great energy: taking steps to conduct global clinical trials in Asia; creating strategies to manufacture and launch their products in Asia; and acquiring new products from Asia to innovate aging product portfolios.

This workshop will concentrate on Asian market access strategies that address the realities of the individual Asian markets,

focusing specifically on how to:

Prepare and execute local Asian regulatory strategies
Design and manage Asian clinical studies in a pan-Asian or even a global context
How to partner and import products
Craft reimbursement, formulary access and comparative effectiveness strategies

Your expert presenters will include:

Alberto Grignolo, Vice President Global Strategy Services, PAREXEL Consulting

Albert Liou, Corporate Vice President, PAREXEL Asia Pacific

James C. Stansel, Partner and co-head Global Life Sciences, Sidley Austin LLP

All workshops are included in your registration fee.

**Please join us for a drink and some hors d'oeuvres after these workshops.

5:45-7:15 Welcome Reception and Registration

Tuesday, October 27, 2009

7:30-8:15 am	Registration & Continental Breakfast
8:20-8:30 am	Welcome
8:30 - 9:30 am	China R & D Roundtable - Bricks & Mortar or Virtual? Lessons Learned From The Trenches More and more big pharmas are moving their R&D operations to China, but do you need a physical presence in China to do innovative R&D? A look at different models for approaching innovation in China: virtual R&D vs. bricks and mortar presence. Big pharma R&D leaders discuss lessons learned from their China experience and the challenges and opportunities. Tony Zhang Managing Director and Site Head Eli Lilly Global R&D, China Li Chen Chief Scientific Officer Roche R&D Center (China) Ltd. Steve Yang VP & Head of R&D Asia Pfizer
9:30-10:30 am	Evolution of the China Biopharma Industry: R & D and Commercial Opportunities and Challenges in the Next 10 Years Given all the talk about R&D and commercial opportunities in China these days, it is sometimes hard to remember how far the China biopharma industry has come in only the last 10 years. Hear from two pioneers of the China biopharma industry about how China has reached this point, and the opportunities and challenges ahead for the next 10 years. Samantha Du CEO Hutchison Pharma Ge Li CEO WuXi Apptec
10:30-11:00 am	Networking Break
11:00-12:15 pm	Fireside Chat: Balancing Dr. Reddy�s Business Model between Generics and Innovative Compounds Started in 1982 by Anji Reddy, Dr. Reddy's Labs has brought many firsts to the Indian pharmaceutical industry, including striking the first research deal with a multinational company for a compound discovered in India. A large part of Dr. Reddy's ambitions have been driven by G V Prasad, and as the company looks to reach the $3 billion mark by 2013, it must balance its business model between the conventional generic industry and growth at the back of its innovative compounds. G.V. Prasad Vice Chairman and CEO Dr. Reddy's Laboratories
12:15 - 1:30 pm	*Lunch*
1:30 - 2:30 pm	Beyond our Borders-What to Expect from U.S. FDA in China and India? With the opening of overseas U.S. FDA offices, the agency and its counterparts in China, India and the Pacific Rim are collaborating more than ever to ensure drug safety and assisting companies in understanding regulatory requirements in the U.S. and across Asia. Key regulatory officials will discuss intra-agency cooperative efforts and the regulatory challenges that remain for the global pharma community. Andrew von Eschenbach Former FDA Commissioner Christopher Hickey Country Director, U.S. FDA, People's Republic of China David Chesney (moderator) Vice President, Strategic Compliance Services PAREXEL Consulting
2:30 - 3:30 pm	Indian Perspective on Globalization: What are the Opportunities and Challenges? Top Indian companies talk about globalization and where they see themselves as well as opportunities India presents. Ramani Aiyer Lifesciences Consultant Piramal Life Sciences Ltd. Ravi Kiron Managing Director Adjuvant Global Advisors, LLC Sridhar Mosur CEO, Global Drug Discovery and Development Jubilant Organosys Limited
3:30 - 4:00 pm	Networking Break
4:00 - 5:30 pm	Partnering For Success In Emerging Markets: How M & A and Licensing in Asia is Transforming the Future of the Pharmaceutical Industry Different models for different reasons: A look at how M&As and licensing deals have changed the face of R&D and the role Asia is playing in that transformation Robert Armstrong VP, Global External Research and Development Eli Lilly and Company Yael Weiss, MD, PhD Director, Licensing And External Research Merck Research Laboratories Jie Liu D'Elia Vice President, International Business Development Simcere Pharmaceutical Group John Throup Director, APJEM R&D Asia Pacific, Japan & Emerging Markets GlaxoSmithKline
5:30-7:00 pm	Cocktail Reception

Wednesday, October 28, 2009

8:30 - 9:00 am	Registration and Continental Breakfast
9:00 -10:00	Investment Outlook For Asia: What Bets should you Make? Asia represents a golden opportunity, especially post global financial crisis - hear from investors about what they are betting on and how companies should be thinking about investing in Asia. Jonathon Wang Senior Managing Director, Asia OrbiMed Advisors Alex Wu CEO Crown Bio Zhu Shen CEO BioForesight Vaibhav Parikh Head, U.S. Office Nishith Desai Associates
10:00-10:30	Networking Break
10:30-11:15	China's Health Care Reform: A Fireside Chat with Song Ruilin When it comes to opportunities for biopharma and medical device companies operating in China, no issue is more important than the government's push for healthcare reform, which promises to deliver universal coverage to China's 1 billion plus citizens by 2020. Yet many key questions - including the make up of an essential medicine list -- remain to be resolved. In a rare opportunity to hear from one of the key health care players in China, learn who will be the winners and losers in China's reform effort, and the impact it will have on product pricing, distribution, and volume in the world's fastest growing life sciences market. Direct From a Key Player in China Healthcare Reform What are the New Opportunities and Challenges to Companies doing Business in China? Song Ruilin Executive Director-General Research Center for Medicinal Policy Chinese Pharmaceutical Association
11:15 - 12:00	Tips for Success: Working and Partnering with a CRO in Asia With two-thirds of the world population, India and China present staggering opportunities for MNCS to conduct clinical trials and preclinical research. Case studies from India and China. Kiran Marthak CEO Veeda Jin Kewen General Manager, China Charles River Laboratories Declan Ryan Executive Director, Business Development ChemPartner
12:00 - 1:00	Building a Commercial Presence in China: Two Companies� Tales China represents the world's fastest growing biopharma market, and many experts predict it will become the second largest market within 10 years. Yet commercialization challenges - including sales, marketing and distribution - are vast. Hear from biopharma leaders about how to take advantage of the immense commercial opportunity, and how to avoid the many potential pitfalls along the way. Jeffery Lange Vice President Business Development SciClone Pharmaceuticals, Inc. Yingfei Wei Chief Scientific Officer and VP Business Development 3SBio Leslie Platt (Moderator) Managing Director & Health Practice Leader Daylight Forensic & Advisory LLC
1:00-2:00	*Lunch*

*invite

Please check back often for more details.

8:20-8:30 am